# UBA Biologix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/uba-biologix

- Industry: Power & Utilities
- Headquarters: San Francisco, US
- Website: www.ubabiologix.co
- Latest round: Seed (May 31, 2017)
- Investors on record: 2

## About

UBA Biologix is focused on developing advanced biological solutions that address critical challenges in healthcare and environmental sectors, offering innovative products to enhance medical treatments and improve sustainability.Founded in 2015 and headquartered in San Francisco, US, UBA Biologix specializes in biological solutions. The company was established by Kagiso Ubane, who has a background in founding technology-driven ventures. UBA Biologix raised seed funding in May 2017, with participation from investors including SOSV and IndieBio.UBA Biologix specializes in the development and provision of advanced biological solutions aimed at addressing critical challenges within the healthcare and environmental sectors. The company's core offerings include innovative biotechnological solutions designed to enhance medical treatment efficacy and improve environmental sustainability. These products serve a diverse clientele, including healthcare providers and research institutions, focusing on delivering high-quality solutions that range from optimizing patient care to improving ecological footprints, with market penetration in North America, Europe, and parts of Asia.UBA Biologix generates revenue through a combination of subscription services and direct sales tailored for business-to-business (B2B) engagements. The company’s transactions are structured around long-term partnerships with healthcare organizations and environmental agencies, facilitating a steady income flow. Flagship products are available under specific pricing plans, allowing clients to engage in bulk purchasing or annual subscriptions for ongoing access to innovative solutions, reflecting the company's commitment to delivering value through its offerings.Looking ahead, UBA Biologix is actively designing new products aimed at enhancing their biological solution range, with anticipated launches in the upcoming year. The company plans to expand into new geographical markets, specifically targeting regions in Asia and the Middle East by late 2024. The recent seed funding raised in May 2017 will be utilized to support these initiatives, as well as to bolster research and development efforts, ensuring a robust pipeline of innovative products.

## Funding rounds

- Seed, May 31, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed